Cencic R, Im YK, Naineni SK, Moustafa-Kamal M, et al. A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer. Proc Natl Acad Sci U S A 2024;121:e2318093121.
PMID: 38232291